Situated near Dhaka, the capital city of Bangladesh, our manufacturing site extends over an area of 23 acres. This main site houses manufacturing facilities for producing various drugs in different strengths and delivery systems such as metered dose inhalers, dry powder inhalers, nebulizer solutions, capsules, tablets, intravenous fluids, sterile ophthalmic drops, prefilled syringes and injectables etc. The site has its own utility infrastructure to ensure adequate generation and distribution of electricity with an installed capacity of 10 MW, in addition to water purifying and liquid nitrogen generation facilities. The bulk drug unit for producing paracetamol is also located within this site while the penicillin API and formulation units are situated at Kaliakoir, a few kilometers from the main site.
Beximco Pharma was among the first few companies in the world who made the transition away from CFC-based inhalers to the ozone benign HFA based formulations, in compliance with the Montreal Protocol. The Company proactively developed ozone benign HFA based MDIs which require very high level of expertise and sophisticated technology. Beximco Pharma is currently the largest producer of MDIs in Bangladesh, and it produces a popular inhaler brand for a global MNC under a contract manufacturing agreement. The MDI units have been designed with the technical collaboration from Pamasol, Switzerland; which now have an annual production capacity of 20 million canisters.
Dry powder inhaler (DPI) is a device that delivers medication to the lungs in the form of a dry powder. DPIs do not require the timing and coordination that are necessary with metered-dose inhaler and they do not contain any propellants. Beximco Pharma offers dry powder inhaler in innovative patient-friendly packaging. Instead of bottle pack, we provide alu-alu blister pack which protects medicine from moisture. HPMC capsule shell ensures maximum protection against moisture. And our unique and simple Bexihaler® device, imported from Europe, and consisting of 8 pins, ensures optimum dose delivery. Currently the facility has the capacity to produce 36 million units of DPI every year.
The state-of-the-art Oral Solid Dosage unit is designed as per US FDA standards. The facility incorporates contemporary technological advancements with automated material handling systems and multilevel designs to enable gravity feed between various processing stages. This facility houses a total of five lines with an annual capacity to produce 5 billion tablets on a single shift basis. Our modern OSD facility is already accredited by the regulatory authorities of EU, Australia and the Gulf member states, and the Company is highly focused on entering the regulated markets of US, EU and Australia.
Beximco Pharma has a broad range of liquid formulations like syrups etc. and semisolid dosage forms including creams and ointments. At present the capacity of liquid dosage facility is 37 million units per annum and the Company has taken up expansion program along with further upgradation of the existing unit to meet the growing demand. The Company currently has the capacity to produce 6 million units of creams and ointments and 10 million units of suppositories.